TY - JOUR

T1 - Male breast cancer in BRCA1 and BRCA2 mutation carriers

T2 - pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

AU - Silvestri, Valentina

AU - Barrowdale, Daniel

AU - Mulligan, Anna Marie

AU - Neuhausen, Susan L

AU - Fox, Stephen

AU - Karlan, Beth Y

AU - Mitchell, Gillian

AU - James, Paul

AU - Thull, Darcy L

AU - Zorn, Kristin K

AU - Carter, Natalie J

AU - Nathanson, Katherine L

AU - Domchek, Susan M

AU - Rebbeck, Timothy R

AU - Ramus, Susan J

AU - Nussbaum, Robert L

AU - Olopade, Olufunmilayo I

AU - Rantala, Johanna

AU - Yoon, Sook-Yee

AU - Caligo, Maria A

AU - Spugnesi, Laura

AU - Bojesen, Anders

AU - Pedersen, Inge Sokilde

AU - Thomassen, Mads

AU - Jensen, Uffe Birk

AU - Toland, Amanda Ewart

AU - Senter, Leigha

AU - Andrulis, Irene L

AU - Glendon, Gord

AU - Hulick, Peter J

AU - Imyanitov, Evgeny N

AU - Greene, Mark H

AU - Mai, Phuong L

AU - Singer, Christian F

AU - Rappaport-Fuerhauser, Christine

AU - Kramer, Gero

AU - Vijai, Joseph

AU - Offit, Kenneth

AU - Robson, Mark

AU - Lincoln, Anne

AU - Jacobs, Lauren

AU - Machackova, Eva

AU - Foretova, Lenka

AU - Navratilova, Marie

AU - Vasickova, Petra

AU - Couch, Fergus J

AU - Hallberg, Emily

AU - Ruddy, Kathryn J

AU - Sharma, Priyanka

AU - Gerdes, Anne-Marie

AU - kConFab Investigators

PY - 2016/2/9

Y1 - 2016/2/9

N2 - BACKGROUND: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).METHODS: We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database.RESULTS: Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10(-12)).CONCLUSIONS: On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.

AB - BACKGROUND: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).METHODS: We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database.RESULTS: Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10(-12)).CONCLUSIONS: On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.

KW - Adult

KW - Aged

KW - BRCA1 Protein

KW - BRCA2 Protein

KW - Breast Neoplasms

KW - Breast Neoplasms, Male

KW - Female

KW - Genetic Predisposition to Disease

KW - Humans

KW - Male

KW - Middle Aged

KW - Mutation

KW - Neoplasm Staging

KW - Polymorphism, Single Nucleotide

KW - Journal Article

U2 - 10.1186/s13058-016-0671-y

DO - 10.1186/s13058-016-0671-y

M3 - Journal article

C2 - 26857456

VL - 18

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

M1 - 15

ER -